Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prediction of hormone sensitivity by DNA microarray.

Shin-Ichi Hayashi1

  • 1Division of Endocrinology, Saitama Cancer Center Research Institute, 818 Komuro, Ina-machi, Saitama, 362-0806, Japan. h.shin@nifty.com

Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|January 24, 2004
PubMed
Summary

This study explored estrogen-responsive genes in breast cancer using DNA microarrays to improve endocrine-therapy prediction. Findings reveal gene expression patterns that may enhance therapeutic strategies for hormone-associated breast cancer.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Resveratrol exhibits diverse anti-cancer activities through epigenetic regulation of E-cadherin and p21 in triple-negative breast cancer cells.

Breast cancer (Tokyo, Japan)·2023
Same author

One DNA Methylation Regulates <i>CHIP</i> Gene Expression of Human Breast Cancer and Predicts Recurrence.

Anticancer research·2022
Same author

Correction to: Molecular targeted drugs resistance impairs double‑strand break repair and sensitizes ER‑positive breast cancer to PARP inhibitors.

Breast cancer (Tokyo, Japan)·2021
Same author

Molecular targeted drugs resistance impairs double-strand break repair and sensitizes ER-positive breast cancer to PARP inhibitors.

Breast cancer (Tokyo, Japan)·2021
Same author

CD4<sup>+</sup> Resident Memory T Cells Mediate Long-Term Local Skin Immune Memory of Contact Hypersensitivity in BALB/c Mice.

Frontiers in immunology·2020
Same author

Heregulin controls ERα and HER2 signaling in mammospheres of ERα-positive breast cancer cells and interferes with the efficacy of molecular targeted therapy.

The Journal of steroid biochemistry and molecular biology·2020

Area of Science:

  • Oncology
  • Molecular Biology
  • Genomics

Background:

  • Endocrine-therapy is crucial for breast cancer treatment, but accurate prediction remains a challenge.
  • The precise role of estrogen and its receptor in estrogen-dependent breast cancer growth requires further elucidation.
  • Developing novel diagnostic tools for endocrine-therapy is highly desired.

Purpose of the Study:

  • To investigate the gene expression profile of estrogen-responsive genes in breast cancer using DNA microarray.
  • To develop a new diagnostic tool for endocrine-therapy prediction.
  • To address the molecular mechanisms of estrogen-dependent breast carcinogenesis.

Main Methods:

  • Large-scale DNA microarray analysis of estrogen responsiveness in estrogen receptor (ER)-positive cancer cell lines.

Related Experiment Videos

  • Selection of 138 estrogen-responsive genes for custom microarray analysis.
  • Validation using real-time RT-PCR and immunohistochemical techniques on breast cancer tissues.

    • Main Results:

    • Identified 138 key estrogen-responsive genes, categorized into early- and late-response types.
    • Custom microarray analysis confirmed large-scale findings and revealed distinct profiles in ER-positive breast cancer tissues compared to cell lines.
    • Candidate genes were identified with potential for predicting endocrine-therapy response.

    Conclusions:

    • Gene expression profiling offers insights into estrogen-dependent breast cancer growth mechanisms.
    • The developed custom microarray shows potential for predicting endocrine-therapy response in breast cancer patients.
    • Further research on identified genes may lead to improved clinical benefit and novel predictive factors for endocrine therapy.